Amunix Presentations

2018

October 2-3
Advances in Immuno-Oncology USA Congress, San Diego
AMX-268 an EpCAM-targeted T cell engager with best in class therapeutic index

June 21-22
Biologics & Biosimilars Congress: USA, Boston
ProTIA – Bispecific T cell engagers designed for local activation in the tumor environment

June 12-14
13th Next Generation Protein Therapeutics and Bioconjugates Summit, San Francisco
ProTIA – Bispecific T cell engagers designed for local activation in the tumor environment

April 30-May 4
14th Annual PEGS: The Essential Protein Engineering Summit, Boston
AMX-268 an EpCAM-targeted T cell engager with best in class therapeutic index

March 5-6
Keynote Address at the 4th Biologics & Biosimilars Congress Europe, Berlin
ProTIA – Bispecific T cell engagers designed for local activation in the tumor environment

January 8-12
17th Annual PepTalk: The Protein Science Week, San Diego
ProTIA – Bispecific T cell engagers designed for local activation in the tumor environment

2017

December 11-15
Antibody Engineering & Therapeutics, San Diego
ProTIA – Bispecific T cell engagers designed for local activation in the tumor environment

Oct.31-Nov. 2
European Antibody Congress, Basel
Highly potent T cell engagers with best-in-class therapeutic index

October 23-25
BioNetwork Partnering Summit at Laguna Niguel, CA
Cancer therapeutics with best-in-class therapeutic index

July 11-12
Antibody & Protein Therapeutics Summit, Baltimore
ProTIA – bispecific T cell engagers designed for activation by tumor-associated proteases based on XTEN® protein polymer

June 5-7
12th Next Generation Protein Therapeutics and Bioconjugates Summit, San Diego
XTEN™ drug linkers achieve high drug loads and limit exposure of healthy tissues

May 1-5
13th Annual PEGS: The Essential Protein Engineering Summit, Boston
ProTIA – a novel format of bispecific T cell engagers designed for activation by tumor-associated proteases

March 6-7
3rd Biologics & Biosimilars Congress, Berlin
XTEN® protein polymer for half-life extension and tumor drug delivery

2016

December 11-15
Antibody Engineering & Therapeutics, San Diego
ProTIA – a novel format of bispecific T cell engagers designed for activation by tumor-associated proteases

November 14-16
European Antibody Congress, Basel
ProTIA – a novel format of bispecific T cell engagers designed for activation by tumor-associated proteases

October 19-21
CPC Symposium, Hangzhou, China
XTEN protein polymer for half-life extension and tumor drug delivery

October 5-7
BioNetwork Partnering Summit at Laguna Niguel, CA
Innovative immuno-oncology platform lead and pipeline compounds available for licensing

May 19-20
Americas Antibody Congress, San Diego
XTEN protein polymer as clinically validated PEG alternative – Use as a high DAR drug linker and for tumor-protease triggered T cell activation

May 9-12
18th Annual TIDES, Long Beach, CA
XTEN protein polymers for half-life extension and tumor drug delivery

April 18-19
3rd Annual Peptides Congress, London
XTEN – a biodegradable alternative to PEGylation with precisely controlled chemical structure

April 4-7
10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow
XTEN protein polymer for half-life extension and tumor drug delivery

February 1-2
2nd Biologics & Biosimilars Congress, Berlin
XTEN™ protein polymer for half-life extension and as a drug linker for ADCs

January 18-22
15th Annual PepTalk: The Protein Science Week, San Diego
Linkers with high drug loads and precisely controlled chemical structure based on XTEN™ long-acting bispecific immune activators